Recently, a study by the team of Tong Chunrong and Liu Shuangyi from Beijing GoBroad Boren Hospital, “Five-year outcomes of CD19 followed by CD22 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia patients who relapsed after allo-transplantation,” was published in Haematologica, the top international journal of hematology (impact factor 8.2).

This study demonstrated that in patients with acute B-lymphoblastic leukemia (B-ALL) who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a very poor prognosis, combination therapy with CD19 and CD22 CAR-T cells dramatically improved long-term survival in this group of patients, with a 5-year overall survival (OS) rate of 75% and an event-free survival (EFS) rate of 50%. This may be an effective treatment for such patients.

More details: https://doi.org/10.3324/haematol.2024.286534